Voyager Therapeutics, Inc.
VYGRHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Voyager Therapeutics, Inc. (VYGR) is listed under Biotechnology. With a market capitalization of $107.2M, it sits in micro-cap territory. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Market Cap
$107.2M
Beta
1.28
P/E (TTM)
—
P/E (Fwd)
-1.36
EPS (TTM)
$-1.81
EPS (Fwd)
$-1.28
ROE
-54.1%
ROA
-27.3%
Cash
$116.3M
Total Debt
$32.6M
Free CF
-$77.3M
52W Change
-63.8%
Annual Financials
Cash vs Debt
Where VYGR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VYGR finished 40.23% below its 150-day moving average ($3.43) and 42.42% below its 200-day moving average ($3.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VYGR overbought or oversold?
At the October 20, 2026 close, VYGR's RSI(14) was 26.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $116.3M in cash comfortably exceeding the $32.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$77.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -54.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $40.9M (2022) to $40.4M (2025).
With cash comfortably exceeding debt, VYGR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VYGR.